• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. 
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Cancer Prevention
    • Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Cancer Prevention
    • Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.

    DOI
    10.1016/j.breast.2015.07.013
    Metadata
    Show full item record
    Abstract
    There are three main ways in which women can be identified as being at high risk of breast cancer i) family history of breast and/or ovarian cancer, which includes genetic factors ii) mammographically identified high breast density, and iii) certain types of benign breast disease. The last category is the least common, but in some ways the easiest one for which treatment can be offered, because these women have already entered into the treatment system. The highest risk is seen in women with lobular carcinoma in situ (LCIS), but this is very rare. More common is atypical hyperplasia (AH), which carries a 4-5-fold risk of breast cancer as compared to general population. Even more common is hyperplasia of the usual type and carries a roughly two-fold increased risk. Women with aspirated cysts are also at increased risk of subsequent breast cancer. Tamoxifen has been shown to be particularly effective in preventing subsequent breast cancer in women with AH, with a more than 70% reduction in the P1 trial and a 60% reduction in IBIS-I. The aromatase inhibitors (AIs) also are highly effective for AH and LCIS. There are no published data on the effectiveness of tamoxifen or the AIs for breast cancer prevention in women with hyperplasia of the usual type, or for women with aspirated cysts. Improving diagnostic consistency, breast cancer risk prediction and education of physicians and patients regarding therapeutic prevention in women with benign breast disease may strengthen breast cancer prevention efforts.
    Authors
    Cuzick, J; Sestak, I; Thorat, MA
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/8411
    Collections
    • Centre for Cancer Prevention [857]
    Language
    ENG

    Related items

    Showing items related by title, author, creator and subject.

    • Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I 

      Warwick, J; Birke, H; Stone, J; Warren, RML; Pinney, E; Brentnall, AR; Duffy, SW; Howell, A; Cuzick, J (2014)
    • Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer 

      Duffy, SW; Morrish, OWE; Allgood, PC; Black, R; Gillan, MGC; Willsher, P; Cooke, J; Duncan, KA; Michell, MJ; Dobson, HM (Elsevier/Science Direct, 2017-11-27)
      Background Mammographic density has been shown to be a strong independent predictor of breast cancer and a causative factor in reducing the sensitivity of mammography. There remain questions as to the use of mammographic ...
    • Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. 

      Canelo-Aybar, C; Ferreira, DS; Ballesteros, M; Posso, M; Montero, N; Solà, I; Saz-Parkinson, Z; Lerda, D; Rossi, PG; Duffy, SW (Sage, 2021-02-25)
      OBJECTIVES: Mammography screening is generally accepted in women aged 50-69, but the balance between benefits and harms remains controversial in other age groups. This study systematically reviews these effects to inform ...
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.